AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06378580
Drug: AG/FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before drug use demographics, blood markers, pathology information# and enhanced CT features.~The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxaliplatin (85 mg/m2), irinotecan (180 mg/m2), leucovorin (400 mg/m2), and 5-fluorouracil (400 mg/m2 bolus, 2400 mg/m2 continuous intravenous infusion for 46 hours) every 14 days. Both the AG and FOLFIRINOX regimens required completion of 6 cycles or until disease progression or unacceptable toxicity.
Trial: NCT05005819
Drug: [18F] APN-1607
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will undergo PET imaging using \[18F\]APN-1607.
Trial: NCT06541704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection
Trial: NCT05114096
Drug: Celestone + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the first intramuscular injection of Celestone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo.
Trial: NCT05114096
Drug: Celestone + Celestone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the first intramuscular injection of Celestone, participants randomized to the Active Comparator group will receive 1 intramuscular injection of Celestone.
Trial: NCT05877573
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200mg/m2 d1-14 q3w
Trial: NCT06390241
Drug: Avidin-biotin-Dota-90Y
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Within 7-8 days after the VABB procedure, 6-10 mg avidin in 1 ml saline will be administered at the site of the occult carcinoma. Subsequently, 90Y DOTA-biotin in the range of 28-57-126 MBq (3 activity levels investigated) will be injected locally immediately after avidin injection.
Trial: NCT05731427
Drug: Macrolides
RxNorm normalized name: Macrolides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before or after 6 months of treatment with macrolides for patients with bronchiectasis
Trial: NCT04609761
Drug: Privigen Injectable Product (Intravenous Immunoglobulin)
RxNorm normalized name: Privigen Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Privigen, 2 g/kg BW every 4th week for 6 months (= 6 infusions).
Trial: NCT05635708
Drug: LBL-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT06731413
Drug: Reduced Dose of Chemotherapy and Immunotherapy
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible participants with recurrent or metastatic squamous cell carcinoma will receive 4 cycles of carboplatin area under the curve (AUC) 3 IV every 21 days and paclitaxel 135 mg/m2 intravenous (IV) every 21 days. Participants with non-squamous histology will receive carboplatin AUC 3 IV every 21 days and pemetrexed 375 mg/m2 IV every 21 days (collectively, induction chemotherapy). Both groups will receive pembrolizumab 200 mg IV every 21 days for a total of up to 35 cycles (Cycles ≥5 are collectively the maintenance portion of treatment) or until disease progression or unacceptable toxicity.
Trial: NCT04619927
Drug: Poor metabolisers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 100mg once daily plus rivaroxaban 2.5mg twice daily
Trial: NCT04619927
Drug: Intermediate metabolisers
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75mg twice daily
Trial: NCT04442412
Drug: RCHOP o R-miniCHOP at standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on both arms receive pre-treatment with prednisone oral before 6 cycles of 21 days each of immunochemotherapy with RCHOP~o R-miniCHOP at standard doses
Trial: NCT04901676
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06159062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo do not consist any active ingredients.
Trial: NCT05106517
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Iv zoledronic acid and placebo /6 months subcutaneously
Trial: NCT05844410
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults patients admitted to the hospital after a confirmed COVID-19 infection, irrespective of the stage and severity of the disease, were included in the study. Only those receiving corticosteroids as a treatment were in the study sample, with no preferences based on race or ethnicity
Trial: NCT05767723
Drug: Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)
Trial: NCT05355597
Drug: Exparel Injectable Product
RxNorm normalized name: Exparel Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs have same desired effect. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
Trial: NCT05355597
Drug: Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same desired effect as Exparel but different mechanism of action. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
Trial: NCT06272409
Drug: DEP114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEP114 oral solution
Trial: NCT05265325
Drug: AND017 capsules TIW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 2 mg/4 mg and 2-weeks interval according to Hb levels
Trial: NCT05265325
Drug: AND017 capsules QW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg/8 mg and 2-weeks interval according to Hb levels
Trial: NCT06228326
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC chemotherapy
Trial: NCT06387147
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin 80 mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
Trial: NCT06387147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin placebo (2ml sodium chloride diluted 1/10 in a syringe of 20mL Metronidazole placebo in tablets
Trial: NCT05273619
Drug: XC8, film-coated tablets, 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day: 4 tablets (40 mg) twice a day
Trial: NCT05273619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets twice a day
Trial: NCT05444699
Drug: Prednisolone Sodium Phosphate
RxNorm normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral suspension administered 1 mg/kg once a day for three days
Trial: NCT05350501
Drug: EO2040
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EO2040, is a therapeutic peptide vaccine composed of two microbial-derived peptides mimicking cytotoxic T cell (CD8+ T cell) epitopes from the Tumor Associated Antigens (TAAs) combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2).~The peptide mix EO2040, i.e. drug product (DP), will be emulsified with the adjuvant Montanide.~EO2040 will be given in combination with nivolumab, which is an anti-PD1. Nivolumab is approved for use for the treatment of multiple cancer types, including subtypes of CRC (mismatch repair deficient or microsatellite instability-high metastatic disease after prior treatment). However, it is not currently approved for ctDNA defined MRD of CRC.
Trial: NCT06066437
Drug: Arm A: 177Lu rhPSMA-10.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 177Lu rhPSMA-10.1 alone.
Trial: NCT05867303
Drug: RC198 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.
Trial: NCT06555497
Drug: topical 1% methotrexate gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical 1% methotrexate gel
Trial: NCT05773183
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In OBS1 20 men will be started on Testosterone replacement therapy as per routine clinical practice. Data collection will occur prior initiating therapy, and 6 months post
Trial: NCT04026464
Drug: Intravenous Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The control monotherapy group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently.
Trial: NCT04026464
Drug: Intravenous Ibuprofen + Oral Acetaminophen
RxNorm normalized name: acetaminophen / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The combined treatment group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently and will in addition receive 15 mg/kg oral acetaminophen \[160 mg/5ml concentration\] every 6 hours for a total of 12 doses.
Trial: NCT06346392
Drug: AZD0901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV
Trial: NCT06346392
Drug: AZD0901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV
Trial: NCT06157918
Drug: SYHA1813 oral solution (2.0g:25mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1813 oral solution, 25mg, oral
Trial: NCT06157918
Drug: SYHA1813 oral solution (20ml:200mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1813 oral solution, 25mg, oral
Trial: NCT06558513
Drug: XNW5004 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous
Trial: NCT05521698
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06480383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet, taken once daily, sublingual administration
Trial: NCT05823532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blinded infusions of saline will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.
Trial: NCT06154863
Drug: RAI
RxNorm normalized name: PRAI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioactive iodine
Trial: NCT05795491
Drug: Azole Antifungal
RxNorm normalized name: Azole antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azole antifungals are a group of medicines that contain an azole ring and inhibit the growth of a wide range of fungi
Trial: NCT05121441
Drug: ARD-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily, oral administration
Trial: NCT05121441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily, oral administration
Trial: NCT05718609
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic for H. pylori eradication
Trial: NCT04835480
Drug: OrsHSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OsrHSA a recombinant HSA, which was expressed and purified from the plant Oryza sativa
Trial: NCT02703610
Drug: Ibuprofen/acetaminophen
RxNorm normalized name: ibuprofen/acetaminophen 125 mg-250 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be discharged home with a 3 day supply of ibuprofen/acetaminophen
Trial: NCT01890941
Drug: KCT-0809 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01890941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05763693
Drug: Azithromycin at Baseline
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at baseline
Trial: NCT05763693
Drug: Azithromycin at Day 21
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at the day 21 visit
Trial: NCT05112328
Drug: Exocrine Pancreatic Enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme supplementation for critically ill patients on enteral nutrition
Trial: NCT05112328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition
Trial: NCT05822518
Drug: Dipeptiven solution (Fresenius Kabi pharmaceutical)
RxNorm normalized name: palmitoyl dipeptide-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipeptiven (Fresenius Kabi pharmaceutical) solution 50 mg o.d IV ( contains L-ananyl-L-glutamine dipeptide) post operatively for 5 days starting from the operation day.
Trial: NCT05241535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT05147051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute
Trial: NCT05070195
Drug: SKLB1028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKLB1028, capsule, oral
Trial: NCT05101785
Drug: Lidocain hydrochloride 2 % with epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia infilteration in children
Trial: NCT05101785
Drug: Articaine chloride 4% with epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine chloride 4% with epinephrine
Trial: NCT04245566
Drug: Pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations
Trial: NCT05901428
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
Trial: NCT05088356
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40mg/kg
Trial: NCT05373277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of placebo twice daily for two days
Trial: NCT05373277
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg tablet, single dose
Trial: NCT04239859
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablet up to 15mg per week
Trial: NCT04908566
Drug: PD-1 antibody combined with SOX program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: oxaliplatin 130 mg/m², d1, ticgio 40-60mg bid, d1-14 q3w;Repeat once every 3 weeks.~2-4 cycles before surgery. The perioperative period was 8 cycles.
Trial: NCT05232071
Drug: IVA337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg
Trial: NCT05232071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match
Trial: NCT06433453
Drug: Indomethacin 50 MG
RxNorm normalized name: indomethacin 50 MG
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The medication is commenced when a preovulatory follicle is observed. It will be administered for a minimum of one day, up to a maximum of 7 days. It will be discontinued when anovulation is observed.
Trial: NCT04982146
Drug: Bromelin
RxNorm normalized name: Bromelin specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg per mL of total tumor volume calculated, administered percutaneously
Trial: NCT04875169
Drug: Core Treatment Active Experimental: SHR0302 Dose#1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
Trial: NCT04875169
Drug: Core Treatment Active Experimental: SHR0302 Dose#2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
Trial: NCT04875169
Drug: Core Treatment Placebo Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
Trial: NCT04875169
Drug: Extension Treatment Active Experimental: SHR0302 Dose#1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
Trial: NCT04875169
Drug: Extension Treatment Active Experimental: SHR0302 Dose#2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
Trial: NCT04842487
Drug: R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide：25mg po QN,d1-10 Rituximab: 375mg/m2, ivdrip, d1 Cyclophosphamide: 750mg/m2, iv or ivdrip, d1 Hydroxyldaunorubicin: 50mg/m2, iv or ivdrip, d1 Vincristine： 1.4 mg/m2 , iv（max：2mg）, d1 Prednisone: 60mg/m2, po, d1-5 every 3 weeks was a course of treatment
Trial: NCT06412224
Drug: RRG001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subretinal injection. Dosage form: injection.
Trial: NCT05890950
Drug: K-757 and K-833
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both administered orally
Trial: NCT05890950
Drug: Matching placebo to K-757 and K-833
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both administered orally
Trial: NCT06473948
Drug: JMKX001899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JMKX001899 500mg tablet, orally once on Day 1
Trial: NCT06473948
Drug: JMKX001899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JMKX001899 750mg tablet, orally once on Day 1
Trial: NCT06473948
Drug: JMKX001899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JMKX001899 1000mg tablet, orally once on Day 1
Trial: NCT06473948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1
Trial: NCT06197490
Drug: Collection of Arterial pressure, metabolic data, kidney function, proteinuria and hematuria before and after KATRIO initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arterial pressure, glycemia, glycated hemoglobin, lipid profile, weight, serum and urinary electrolytes, hepatic check, complete blood count, calcium phosphate balance and urinary sediment analysis before and after initiation of KAFTRIO
Trial: NCT06054932
Drug: LK101 injection
RxNorm normalized name: BANDAGE KIT,COMPRESSION LYMPHEDEMA#LK101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LK101 administrated Q2W as the prime dose, and Q3W in the boost phase
Trial: NCT06054932
Drug: LK101 injection
RxNorm normalized name: BANDAGE KIT,COMPRESSION LYMPHEDEMA#LK101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LK101 administrated QW as the prime dose, and Q3W in the boost phase
Trial: NCT04780399
Drug: Yangxue Qingnao pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72 subjects in the Yangxue Qingnao pills group take 7.5g of Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
Trial: NCT04780399
Drug: Yangxue Qingnao pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72 subjects in the Yangxue Qingnao pills group take 5g of Yangxue Qingnao pills and 2.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
Trial: NCT04780399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72 subjects in the placebo group take 7.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
Trial: NCT05401357
Drug: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
Trial: NCT04956419
Drug: SHR8008 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 2 days(Day 1 and Day 2),oral
Trial: NCT02368613
Drug: DW-3102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00347503
Drug: ketorolac 0.4%, bromfenac 0.09%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05108623
Drug: agenT-797
RxNorm normalized name: MISCELLANEOUS AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Trial: NCT05587088
Drug: Petiveria Alliacea Preparation
RxNorm normalized name: Petiveria alliacea preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petiveria Alliacea Preparation in pill
Trial: NCT05095064
Drug: Onivyde® + 5-FULV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanoliposomal irinotecan (Onivyde®) in combination with 5-fluorouracil and leucovorin (5-FU/LV)